CO2020004831A2 - Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa - Google Patents

Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa

Info

Publication number
CO2020004831A2
CO2020004831A2 CONC2020/0004831A CO2020004831A CO2020004831A2 CO 2020004831 A2 CO2020004831 A2 CO 2020004831A2 CO 2020004831 A CO2020004831 A CO 2020004831A CO 2020004831 A2 CO2020004831 A2 CO 2020004831A2
Authority
CO
Colombia
Prior art keywords
administration
treatment
antibodies
patients
dosage
Prior art date
Application number
CONC2020/0004831A
Other languages
English (en)
Inventor
Giuseppe Remuzzi
Piero Ruggenenti
Xiang Gao
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of CO2020004831A2 publication Critical patent/CO2020004831A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RESUMEN Se proporcionan métodos para el tratamiento clínico de la glomerulonefritis membranoproliferativa (GNMP) mediante la administración de un anticuerpo anti-C5, o su fragmento de unión a antígeno.
CONC2020/0004831A 2017-10-04 2020-04-20 Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa CO2020004831A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568060P 2017-10-04 2017-10-04
US201862652615P 2018-04-04 2018-04-04
PCT/US2018/053976 WO2019070714A1 (en) 2017-10-04 2018-10-02 ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT

Publications (1)

Publication Number Publication Date
CO2020004831A2 true CO2020004831A2 (es) 2020-05-29

Family

ID=64051671

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0004831A CO2020004831A2 (es) 2017-10-04 2020-04-20 Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa

Country Status (11)

Country Link
US (2) US20200262897A1 (es)
EP (2) EP4424324A3 (es)
JP (2) JP2020536097A (es)
KR (1) KR20200059279A (es)
CN (1) CN111278857A (es)
AU (1) AU2018345625A1 (es)
BR (1) BR112020006692A2 (es)
CA (1) CA3078362A1 (es)
CO (1) CO2020004831A2 (es)
MX (1) MX2020003619A (es)
WO (1) WO2019070714A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA
US20210215714A1 (en) * 2018-05-25 2021-07-15 Achillion Pharmaceuticals, Inc. Complement alternative pathway-associated nephropathy biomarkers
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
EP3898617A4 (en) 2018-12-17 2022-08-17 Achillion Pharmaceuticals, Inc. TARGETED DOSAGE FOR THE TREATMENT OF COMPLEMENT INDUCED DISORDERS
US12479856B2 (en) 2019-03-22 2025-11-25 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP2018520139A (ja) * 2015-06-26 2018-07-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
WO2017217524A1 (en) * 2016-06-17 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use

Also Published As

Publication number Publication date
CA3078362A1 (en) 2019-04-11
JP2020536097A (ja) 2020-12-10
AU2018345625A1 (en) 2020-04-16
US20200262897A1 (en) 2020-08-20
WO2019070714A1 (en) 2019-04-11
KR20200059279A (ko) 2020-05-28
MX2020003619A (es) 2020-10-28
US20240025975A1 (en) 2024-01-25
EP4424324A2 (en) 2024-09-04
EP4424324A3 (en) 2024-11-06
BR112020006692A2 (pt) 2020-10-06
JP2023101717A (ja) 2023-07-21
EP3692064A1 (en) 2020-08-12
CN111278857A (zh) 2020-06-12

Similar Documents

Publication Publication Date Title
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
CO2020004838A2 (es) Dosis y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxística nocturna (hpn) y el síndrome hemolítico urémico atípico (shua)
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
MX2021008919A (es) Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua).
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
PH12019502361A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
IL285923A (en) Compositions, methods, and kits for delivery of polyribonucleotides
ECSP16060104A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
JO3537B1 (ar) أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة
EA201790475A1 (ru) Способы лечения системной красной волчанки с использованием доменного антитела против cd28
CY1123982T1 (el) Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2021009789A (es) Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.
DK3394045T3 (da) Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal.
HUE063119T2 (hu) Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez
MX2019007107A (es) Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
HUE052528T2 (hu) Anti szklerosztin antitest, antigénkötõ fragmens és annak orvosi használata